Literature DB >> 10978943

Prediction of hepatitis C burden in Canada.

S Zou1, M Tepper, S El Saadany.   

Abstract

To assess the risk of hepatitis C in Canada and to predict the burden that this disease may pose to the Canadian society in the near future, expected numbers of persons at different stages of the disease currently and in the next decade were estimated by simulation using a published hepatitis C natural history model with no treatment effect being applied. Based on the estimate of 240,000 persons who are currently infected with the hepatitis C virus in Canada, the simulation analysis demonstrated that the number of hepatitis C cirrhosis cases would likely increase by 92% from 1998 to the year 2008. It was also projected that the number of liver failures and hepatocellular carcinomas related to hepatitis C would increase by 126% and 102%, respectively, in the next decade. The number of liver-related deaths associated with hepatitis C is expected to increase by 126% in 10 years. The medical and social care systems in Canada may not be ready to support these large increases. These results highlight the importance of both the control of disease progression of hepatitis C virus-infected persons and the primary prevention of hepatitis C infections in Canada.

Entities:  

Mesh:

Year:  2000        PMID: 10978943     DOI: 10.1155/2000/642707

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  21 in total

1.  Hepatitis C update.

Authors:  Shimian Zou; Leslie Forrester; Antonio Giulivi
Journal:  Can J Public Health       Date:  2003 Mar-Apr

2.  Pay now or pay (more) later: tracking the costs of hepatitis C infection.

Authors:  Robert P Myers; Samuel S Lee
Journal:  Can J Gastroenterol       Date:  2010-12       Impact factor: 3.522

Review 3.  Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop.

Authors:  Kymberly D S Watt; Kelly Burak; Marc Deschênes; Les Lilly; Denis Marleau; Paul Marotta; Andrew Mason; Kevork M Peltekian; Eberhard L Renner; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2006-11       Impact factor: 3.522

4.  Hepatitis C: the juggernaut rolls on unchecked.

Authors:  Morris Sherman
Journal:  Can J Gastroenterol       Date:  2008-04       Impact factor: 3.522

Review 5.  Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies.

Authors:  John B Wong
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada.

Authors:  Sergio M Borgia; Adenike Rowaiye
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04

7.  HIV and hepatitis C virus testing and seropositivity rates in Canadian federal penitentiaries: A critical opportunity for care and prevention.

Authors:  Prithwish De; Nancy Connor; Françoise Bouchard; Donald Sutherland
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-07       Impact factor: 2.471

8.  Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.

Authors:  Benedikt Fischer; Emma Haydon; Jürgen Rehm; Mel Krajden; Jens Reimer
Journal:  J Urban Health       Date:  2004-09       Impact factor: 3.671

9.  An epidemiologic study of hepatocellular carcinoma in Canada.

Authors:  Susie elSaadany; Martin Tepper; Yang Mao; Robert Semenciw; Antonio Giulivi
Journal:  Can J Public Health       Date:  2002 Nov-Dec

10.  Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients.

Authors:  Maciej Witkos; Qi-Long Yi; Jenny Heathcote; Moira K Kapral; Murray D Krahn
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.